GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to ...
Give clients a better understanding of risk comfort and trade-offs with a data-backed risk profile. Our risk tolerance questionnaire has been taken over 2 million times with stable and defensible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback